What Happens to Your GLP-1 Provider If Compounding Gets Banned?
The FDA's proposed rule sent shockwaves through the telehealth GLP-1 market. Here's what each type of provider is doing to prepare — and how it affects you.
The Three Types of GLP-1 Telehealth Providers
Type 1: Already Pivoting to Brand-Name
Major platforms like Hims & Hers have already announced partnerships with Novo Nordisk to offer brand-name semaglutide. These companies saw the regulatory writing on the wall and are positioning themselves as brand-name access platforms rather than compounding middlemen.
What this means for patients: Expect higher prices but more stability. Your medication supply won't be disrupted by regulatory changes.
Type 2: Doubling Down on 503A (Individual Compounding)
Some telehealth providers are routing patients through 503A pharmacies that compound individual prescriptions. Since the proposed rule targets 503B facilities specifically, this pathway may remain legal.
What this means for patients: Continued access to compounded options, but potentially with less consistency and higher per-unit costs as 503A pharmacies can't achieve bulk manufacturing efficiencies.
Type 3: Additive Differentiation Strategy
IQVIA research found that over 80% of compounded GLP-1 prescriptions now include supplemental ingredients like B vitamins or levocarnitine. Some providers are framing these as "differentiated formulations" rather than copies of brand-name drugs.
What this means for patients: Regulatory risk is highest here. The FDA has signaled that adding inactive ingredients to create a nominally different product may not be sufficient to avoid enforcement.
Red Flags to Watch For
• Guarantees compounded GLP-1 availability "no matter what the FDA does"
• Won't discuss brand-name transition options
• Requires you to prepay 6+ months to "lock in" compounded pricing
• Can't identify their compounding pharmacy by name and license type
Your Action Plan
Step 1: Ask your provider what type of pharmacy compounds your medication. If they use a 503B outsourcing facility, that supply chain is directly at risk. If they use a 503A pharmacy, it's less immediately threatened.
Step 2: Check your insurance. Many 2026 plans have expanded GLP-1 coverage. Even a prior authorization denial is worth appealing — the approval rate on appeals is higher than most patients expect.
Step 3: Explore brand-name self-pay. With starting doses at $149/mo, the price difference may be smaller than you think.
Step 4: Don't stockpile. Compounded GLP-1s have stability and sterility considerations. Hoarding medication is both medically inadvisable and likely to result in wasted product.